AstraZeneca Voluntarily Withdraws Imfinzi Indication in Locally Advanced or Metastatic Bladder Cancer
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
Loxo Oncology is preparing to initiate the global, randomized, BRUIN MCL-321 superiority study in patients with Bruton tyrosine kinase inhibitor-naïve disease.
The plenary program will include talks on sickle cell disease, hematologic malignancies, resistance mechanisms, and treatment disparities.
Does abemaciclib and letrozole effective slow or stop endometrial cancer cell growth?
All patients will receive mirvetuximab soravtansine and pembrolizumab in this study.
A phase 3 study seeks to evaluate the value of selecting therapy based on molecular profiling.
Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.
The objective of the study is to investigate PVSRIPO-mediated inflammation and immunity in women invasive breast cancer.
Barriers to breast cancer screening for certain minority groups have been studied, but less is known about the barriers for African immigrant women.
Enrolled patients will undergo standard of care lumpectomy without sentinel node biopsy followed by radiation and hormonal therapy.